BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32449240)

  • 1. Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer.
    Kanno H; Miyoshi H; Yoshida N; Sudo T; Nakashima K; Takeuchi M; Nomura Y; Seto M; Hisaka T; Tanaka H; Okuda K; Akagi Y; Ohshima K
    Cancer Sci; 2020 Aug; 111(8):3032-3044. PubMed ID: 32449240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
    Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
    Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
    Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
    Front Immunol; 2021; 12():778329. PubMed ID: 34975867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD169
    Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
    Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer.
    Jung DH; Park HJ; Jang HH; Kim SH; Jung Y; Lee WS
    Cancer Invest; 2020 Aug; 38(7):406-414. PubMed ID: 32762373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder.
    Hodgson A; Vesprini D; Liu SK; Xu B; Downes MR
    J Clin Pathol; 2020 Aug; 73(8):519-522. PubMed ID: 31919144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
    Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
    Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
    [No Abstract]   [Full Text] [Related]  

  • 13. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
    Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
    Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study.
    Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P
    Front Immunol; 2022; 13():809971. PubMed ID: 35185898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
    Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
    Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
    Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
    Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
    Sinicrope FA; Rego RL; Ansell SM; Knutson KL; Foster NR; Sargent DJ
    Gastroenterology; 2009 Oct; 137(4):1270-9. PubMed ID: 19577568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Adaptive Immune Landscape of the Colorectal Adenoma-Carcinoma Sequence.
    Freitas JA; Gullo I; Garcia D; Miranda S; Spaans L; Pinho L; Reis J; Sousa F; Baptista M; Resende C; Leitão D; Durães C; Costa JL; Carneiro F; Machado JC
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.